Operator: Good morning. And welcome to the Cadence Pharmaceuticals Fourth Quarter and Full Year 2010 Financial Results Conference Call. On the call today are Ted Schroeder, President and CEO; Bill LaRue, Senior Vice President and Chief Financial Officer; Jim Breitmeyer, Executive Vice President and Chief Medical Officer and Scott Byrd, Senior Vice President and Chief Commercial Officer.
At this time, I would like to inform you that this conference is being recorded and that all participants are in a listen-only mode. At the request of the Company, we will open the conference up for questions and answers after the management presentation.
Our first speaker is Bill LaRue. Go ahead, sir.
William R. LaRue - SVP, CFO, Treasurer and Assistant Secretary: Thank you. Good morning, everyone. Before we get started today, I'd like to remind you that statements included in this conference call that are not a description of historical facts are forward-looking statements. Such forward-looking statements include statements regarding the anticipated U.S marketing opportunity for IV acetaminophen, our ability to achieve formulary and market acceptance for OFIRMEV, our strategy for building a long term hospital pain franchise, the sufficiency of our capital resources to fund our operations and our financial estimates or projections. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
Our actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in our business. These risks include our dependence on the successful commercialization of OFIRMEV; the risk of delays in achieving formula acceptance for OFIRMEV at a substantial number of targeted accounts, would enable competitors to further entrench their products and decrease the market potential for OFIRMEV; our ability to ensure an adequate and continued supply of OFIRMEV, to meet anticipated market demand, and the fact that OFIRMEV remains subject to substantial ongoing regulatory requirements; the potential that we may be required to file a law suit to defend our patent rights, the regulatory exclusivities from challenges by companies seeking to market generic versions of intravenous acetaminophen; our ability to successfully enforce our intellectual property rights and defend our patents; the risk that we may not be able to raise efficient capital when needed; and other risk detailed under the risk factors and elsewhere in our periodic reports and other filings made with the Securities and Exchange Commission from time to time.
All forward-looking statements are qualified in their entirety by this cautionary statement, which is provided under the Safe Harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and we undertake no obligation to revise or update the information discussed during this call to reflect events or circumstances after this call. If anyone has not seen our press release issued yesterday, you can assess it in our website at www.cadencepharm.com. Additionally, this conference call is being webcast through our website and will be archived there for future reference. Ted?